Resumen
Background: Bright light therapy has been shown to improve depressive symptoms in patients with nonseasonal major depressive disorder (MDD) but there are few studies examining functional outcomes. Methods: We examined secondary functional outcomes in the 8-week randomized, placebo-sham-controlled LIFE-D trial comparing light therapy, fluoxetine, and the combination in patients with nonseasonal MDD. Functional assessments included the Sheehan Disability Scale (SDS) and, for employed participants, the Lam Employment Absence and Productivity Scale (LEAPS). Analysis of covariance (ANCOVA) was conducted with SDS and LEAPS change scores from baseline to week 8 as dependent variables, treatment modality (light, fluoxetine) as an independent variable, and baseline SDS and LEAPS scores as covariates. Results: Of 122 randomized participants, SDS data were available for 105 and LEAPS data for 70. For the SDS, there were no interaction effects, but there was a significant small- to medium-sized main effect of light treatment on total SDS scores with corresponding significant effects in the Social Life and Family Life domains, but not in the Work/Study domain. There were no significant interaction or main effects with LEAPS scores. Conclusion: Light therapy significantly improved social and family life functioning in patients with MDD. However, work functioning was not significantly improved despite large effect sizes; these results were limited by low statistical power because of small sample sizes. Future studies should use longer treatment durations and be powered to detect clinically relevant differences in functional outcomes.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 396-400 |
Número de páginas | 5 |
Publicación | Journal of Affective Disorders |
Volumen | 297 |
DOI | |
Estado | Published - ene. 15 2022 |
Nota bibliográfica
Funding Information:This work was supported by the Canadian Institutes of Health Research [Grant No. MCT-94832 ]. The funding agency had no role in the design, data collection, analysis, interpretation, or publication of this study.
Funding Information:
EE has received funding to support patient education initiatives from Otsuka. RR has received honoraria or research grants from Alberta Innovates and Health Solutions (AIHS), Astra Zeneca, Janssen, Lundbeck, Otsuka and Pfizer. LNY has received honoraria or research grants from AbbVie, Allergan, Canadian Network for Mood and Anxiety Treatments (CANMAT), DSP, Intracellular Therapies, Lundbeck, Merck, Otsuka, Sanofi, and Sunovion. RWL has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Canadian Institutes of Health Research, CANMAT, Janssen, Lundbeck, Lundbeck Institute, Michael Smith Foundation for Health Research, MITACS, Ontario Brain Institute, Otsuka, Pfizer, Unity Health, and Vancouver General Hospital Foundation. The other authors have no disclosures to report.
Publisher Copyright:
© 2021 Elsevier B.V.
ASJC Scopus Subject Areas
- Clinical Psychology
- Psychiatry and Mental health
PubMed: MeSH publication types
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't